ArticleBMC cancer2017
A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.
Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 1 synthesis or guideline pooled it, 193 citations in OpenAlex.
- Use of nanoparticles in animal models for prostate cancer treatment: a systematic review.Acta cirurgica brasileira · 2023Pooled it
- Preclinical Pharmacokinetic-Pharmacodynamic Modeling of Antibody Nanoconjugates for Breast Cancer Treatment.CPT: pharmacometrics & systems pharmacology · 2026Article
- A novel tetrahydrocurcumin derivative as a potential anti-colorectal cancer agent: studies on its design, synthesis, and in vitro and in vivo biological evaluation.Natural products and bioprospecting · 2026Article
- Differential impact of cancer- and chemotherapy-induced cachexia: a comparative analysis in a preclinical model of colorectal cancer by biological sex.American journal of physiology. Endocrinology and metabolism · 2026Article
- Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy.Signal transduction and targeted therapy · 2026Article
- In Silico Drug Repositioning Identifies SYK Kinase Inhibitors as Potential Neuroprotective Agents for Ataxia-Telangiectasia.Chemical biology & drug design · 2026Article
- Microrobotic copper-rich electrochemical interfacing for targeted cancer theranostics in the gut.Science advances · 2026Article
- Evaluation of Arabica coffee pulp extract on sperm quality and hematology in cyclophosphamide-treated rats.Environmental analysis, health and toxicology · 2026Article
- All-PEG-Like Block Copolymers Self-Assemble into Stealth Nanocarriers for Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Determination of the optimal cisplatin dose to induce anemia in streptozotocin-nicotinamide-induced type 2 diabetic rats: A preliminary study.Open veterinary journal · 2026Article
- Influences of formulations and administration routes on docetaxel tissue distribution in mice.Scientific reports · 2026Article
- Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer.AAPS PharmSciTech · 2025Article
- Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3).Journal of the American Chemical Society · 2025Article
- Loss-of-function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5-fluorouracil and irinotecan treatment in colorectal cancer.Clinical and translational medicine · 2025Article
- Article
- The Convergence of Biology and Material Science: Biomolecule-Driven Smart Drug Delivery Systems.Biomolecules · 2025Review
- Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death.Angewandte Chemie (International ed. in English) · 2025Article
- Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death.Cells · 2025Article
- Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells.EJNMMI research · 2025Article
- Pt(IV)-functionalised polyacrylic acid-coated iron oxide magnetic nanoparticles as redox-responsive cancer theranostics.Journal of materials chemistry. B · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytotoxic chemotherapeutics form the cornerstone of systemic treatment of many cancers. Patients are dosed at maximum tolerated dose (MTD), which is carefully determined in phase I studies. In contrast, in murine studies, dosages are often based on customary practice or small pilot studies, which often are not well documented. Consequently, research groups need to replicate experiments, resulting in an excess use of animals and highly variable dosages across the literature. In addition, while patients often receive supportive treatments in order to allow dose escalation, mice do not. These issues could affect experimental results and hence clinical translation.
methodsTo address this, we determined the single-dose MTD in BALB/c and C57BL/6 mice for a range of chemotherapeutics covering the canonical classes, with clinical score and weight as endpoints.
resultsWe found that there was some variation in MTDs between strains and the tolerability of repeated cycles of chemotherapy at MTD was drug-dependent. We also demonstrate that dexamethasone reduces chemotherapy-induced weight loss in mice.
conclusionThese data form a resource for future studies using chemotherapy in mice, increasing comparability between studies, reducing the number of mice needed for dose optimisation experiments and potentially improving translation to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.